Evidence map›Paper›PMID 37746279›Full record

ArticleFrontiers in oncology2023

Impact of oncoplasty in increasing breast conservation rates Post neo-adjuvant chemotherapy.

Chaitanyanand B Koppiker, Devaki A Kelkar, Madhura Kulkarni, Shweta Kadu, Mugdha Pai, Upendra Dhar, Chetan Deshmukh, Beenu Varghese, Vaishali Zamre, Nutan Jumle and 11 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Chaitanyanand B KoppikerPrashanti Cancer Care Mission, Pune, India.
Devaki A KelkarPrashanti Cancer Care Mission, Pune, India.
Madhura KulkarniPrashanti Cancer Care Mission, Pune, India.
Shweta KaduPrashanti Cancer Care Mission, Pune, India.
Mugdha PaiPrashanti Cancer Care Mission, Pune, India.
Upendra DharDepartment of Onco-Sciences, Jehangir Hospital, Pune, India.
Chetan DeshmukhDepartment of Onco-Sciences, Jehangir Hospital, Pune, India.
Beenu VargheseDepartment of Onco-Sciences, Jehangir Hospital, Pune, India.
Vaishali ZamreInternational School of Oncoplasty, Pune, India.
Nutan JumleDepartment of Onco-Sciences, Jehangir Hospital, Pune, India.
Nutan GangurdePrashanti Cancer Care Mission, Pune, India.
Anjali JoshiPrashanti Cancer Care Mission, Pune, India.
Rohini UndePrashanti Cancer Care Mission, Pune, India.
Rituja BanalePrashanti Cancer Care Mission, Pune, India.
Namrata NamewarPrashanti Cancer Care Mission, Pune, India.
Pooja VaidCenter for Translational Cancer Research, a Joint venture between Prashanti Cancer Care Mission and Indian Institute of Science Education and Research (IISER), Pune, India.
Laleh BusheriPrashanti Cancer Care Mission, Pune, India.
George ThomasOrchids Breast Health Centre, A Prashanti Cancer Care Mission (PCCM) Initiative, Pune, India.
Smeeta NarePrashanti Cancer Care Mission, Pune, India.
Jerome PereiraNorwich Medical School, University of East Anglia, Norwich, United Kingdom.
Sunil BadveDepartment of Pharmacology and Chemical Biology, Emory University, Atlanta, GA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The essential goal of neoadjuvant chemotherapy (NACT) is to downstage the primary tumor making it amenable for breast conservation surgery (BCS). However, since the safety of this surgery is paramount, post-NACT breast conservation rates remain low. As per the recommendation of the 2018 Early Breast Cancer Trialists' Collaborative Group (EBCTCG) overview of long-term post-NACT follow-up, we have devised a protocol for imaging, localization, rad-path analysis, and documentation of radiotherapy techniques to ensure the safety of post-NACT breast conservation. Methods: This is a retrospective cohort of 180 breast cancer patients who received NACT and were operated on by a single surgical oncologist from 2015 to 2020. After selection based on published guidelines, patients were treated with neoadjuvant systemic (chemo or hormone) therapy. In cases where primary tumors responded and reduced to 1-2 cm in size mid-NACT, the residual tumors were localized by clips under ultrasound guidance and calcification was wire localized. All patients were treated using appropriate surgical and oncoplastic techniques where indicated. Negative margins were ensured by intra-operative rad-path analysis. Adjuvant chemotherapy and radiotherapy were given as per protocol. Results: In 81 cases that required mastectomy at presentation, we were able to achieve a 72.8% post-NACT BCS rate with the help of oncoplasty. Overall, 142 of 180 (80%) patients were treated with breast conserving surgery of which 80% (121 of 142) were oncoplasty. Margins were assessed on intra-operative frozen and re-excised in the same setting. No positive margins were reported in final histopath of 142 breast conservation procedures. Post-operative complication rates after breast conservation in the first year were at 17% (24 of 142 including two major complications). Patient reported outcomes were satisfactory with increased satisfaction for breast conservation compared with immediate breast reconstruction. Discussion: Employing oncoplastic breast surgery (OBS) techniques following stringent protocols for accurate localization of the residual tumor, intra-operative rad-path analysis, and adjuvant treatments, we show successful breast conservation in 72.8% of our mastectomy-qualified patients after downstaging by NACT. We also report satisfactory outcomes for post-NACT surgery, patient-reported satisfaction, and survival.

Indexed as

breast cancerbreast conservation for large tumorsfrozen section analysismastectomyneoadjuvant chemotherapyoncoplastic breast conservationtumor localization

Identifiers

PMID37746279
PMCPMC10514208

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.